Phibro Animal Health Reports Surging Q2 Profits, Raises Full-Year Guidance

summarizeSummary

Phibro Animal Health announced outstanding Q2 FY2026 results, with net income up over 700% and adjusted EBITDA up 41%, leading to a significant raise in full-year guidance.

check_boxKey Events

• Exceptional Q2 FY2026 Financial Performance

  Net sales increased 21% to $373.9 million, and net income surged over 700% to $27.5 million for the quarter ended December 31, 2025.

• Strong Profitability Growth

  Adjusted EBITDA rose 41% to $68.1 million, and adjusted diluted EPS increased 58% to $0.87, demonstrating robust operational efficiency.

• Raised Full-Year Guidance

  The company significantly increased its fiscal year 2026 guidance, now projecting net sales of $1.45 billion to $1.50 billion and adjusted EBITDA of $245 million to $255 million.

• Successful Strategic Execution

  CEO Jack Bendheim highlighted faster-than-expected uptake of the newly integrated MFA portfolio and sustained growth in nutritional specialty and vaccine offerings as key drivers.

auto_awesomeAnalysis

Phibro Animal Health Corporation reported exceptionally strong financial results for the second quarter of fiscal year 2026, with net income surging over 700% year-over-year and adjusted EBITDA increasing by 41%. This robust performance, driven by successful integration of its MFA portfolio and sustained growth in other segments, led the company to significantly raise its full-year fiscal 2026 guidance for both net sales and adjusted EBITDA. This positive announcement, made via press release furnished in this 8-K and detailed in the concurrently filed 10-Q, reinforces investor confidence, especially as the stock is trading near its 52-week high.